Farallon launches Exelixis proxy fight

(Hedgeweek) Hedge fund Farallon Capital Management is planning to launch a proxy fight at biotech Exelixis Inc with the nomination of three directors to the board of the cancer drug maker, according to a report by The Wall Street Journal (WSJ).

To read this article:

This entry was posted in Syndicated. Bookmark the permalink.

Comments are closed.